Redeye updates its estimates following CTEK’s Q3 report, which was better than we expected. We were most impressed by the low-voltage sales, which managed to generate 16% organic growth y-o-y. This was the key driver of the adjusted EBITA margin, which increased to 14% in the quarter. CTEK has kept improving in sales and profitability for every quarter during the last year, and we think the outlook remains solid for both the consumer- and professional segment as we are heading into Q4, which typically is the strongest quarter of the year for CTEK.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/